
Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target
Adaptive Biotechnologies (ADPT) Analyst Ratings
Bulls say
Adaptive Biotechnologies Corp is positioned for strong financial growth, driven by improvements in clinical average selling prices (ASP) and a favorable clinical mix shift. The transition to the NovaSeq X platform is anticipated to increase sequencing margins, supporting the overall gross profit outlook for the company. Furthermore, the expected growth in minimal residual disease (MRD) diagnostics, alongside rising ASPs and incremental volume increases, is projected to enhance both top-line revenue and gross margins significantly by 2025.
Bears say
Adaptive Biotechnologies is facing a stagnant revenue outlook in its Immune Medicine division, as no growth value is anticipated while the company works to generate interest in its TCR-Antigen model and develop its autoimmunity program. A concerning statistic indicates that approximately 25% of patients receiving an ID test do not obtain a minimal residual disease (MRD) result within the subsequent 12 months, potentially hindering the frequency of average tests conducted. Despite being a leader in the market, the company is grappling with significant challenges that may limit its growth potential in the near future.
This aggregate rating is based on analysts' research of Adaptive Biotechnologies and is not a guaranteed prediction by Public.com or investment advice.
Adaptive Biotechnologies (ADPT) Analyst Forecast & Price Prediction
Start investing in Adaptive Biotechnologies (ADPT)
Order type
Buy in
Order amount
Est. shares
0 shares